Scott A. Estes
Analyst · Bank of America
Thanks, guys, and good morning, everyone. I'm happy to report that our financial position remains strong. Our capital structure continues to provide the consistent and resilient financial results you've come to expect from Health Care REIT. I have 3 simple points that I'd like to emphasize today: first, our recent $400 million debt offering provides incremental balance sheet flexibility and liquidity; second, the significant $5 billion of investments completed year-to-date is now translating into more meaningful earnings growth, both for this year and next; and third, our confidence in future earnings growth has enabled us to announce a 4% increase in our 2014 dividend payment rate today. I'll start with some general housekeeping items related to our balance sheet and liquidity. I'm pleased with where the balance sheet stands today. As of September 30, our net debt-to-undepreciated book capitalization was 42.2%. Currently, our debt to adjusted EBITDA is right at the 6x level, while our adjusted interest and fixed charge coverage improved to 3.6x and 2.8x, respectively. These metrics are all in line with our strategic targets. In terms of capital and liquidity, we continue to enjoy solid access to the capital markets and have efficiently raised capital to fund the majority of transactions announced year-to-date. There were 3 significant capital events which have occurred since I last spoke to you in August. First, we issued just over 1 million shares under our dividend reinvestment program during the third quarter, generating $62 million in proceeds. Second, $219 million of our outstanding 3% convertible debt was redeemed or converted during the quarter, leaving $275 million outstanding. And finally, in early October, we were able to successfully raise $400 million of long-tenure unsecured debt price deal of 4.6%. This debt fits nicely into our maturity schedule and speaks to the ongoing support provided by the capital markets. Let's now look at the anticipated line of credit borrowings through year end, which will exclude the effects of any additional investments. So starting on September 30, our balance sheet shows that we had $165 million in cash and $848 million borrowed on our credit lines, resulting in $683 million of net line borrowings at quarter-end. After taking into account the $393 million of net proceeds from our October debt offering, these net borrowings are further reduced to $290 million. For the remainder of the year, we expect an additional $375 million of line borrowings as a result of: first, $300 million in unsecured debt with a 6% coupon maturing in November; an additional $75 million of secured debt we intend to pay off; about $100 million of projected fourth quarter development funding; less $100 million of anticipated fourth quarter disposition proceeds. So as a result, we're on track to have about $665 million of net line borrowings at year-end, providing a significant $1.6 billion of line availability net of these borrowings. Despite the recent market instability, our incremental cost of capital remains near historically low levels and has actually improved somewhat over the last several weeks. The weaker economic data and the Fed's potential delay in tapering asset purchases has contributed to lower interest rates in, generally, health and health care REIT stocks. Thus far, in 2013, our equity has generally performed in line with the REIT sector, generating a solid total return of approximately 10% year-to-date. Our incremental cost of debt also remains attractive based on current treasury yields and spreads. As a result, we continue to have access to attractively priced capital as we source new investments through year end and into 2014. Moving now to our third quarter earnings results. Our continued success on the investment front has translated into more significant earnings growth. Normalized FFO increased to a record $0.97 per share for the quarter, representing a strong 7% increase versus last year. Third quarter normalized FAD per share of $0.86 represented an increase of 5% year-over-year. Our FFO and FAD payout ratios for the quarter declined to 79% and 89%, respectively. Results were again driven by the combination of strong internal growth in the form of a 3.7% increase in same-store NOI, and external growth in the form of $6.7 billion of net investments completed over the last 12 months. And, finally, I'll conclude today with an update on our dividend payments, our enhanced disclosure efforts and guidance. We declared our 170th consecutive quarterly cash dividend for the quarter ended September 30 of $0.765 per share or $3.06 annually. This represents a 3.4% increase over the dividends paid in 2012 and a current dividend yield of 4.7%. As we move into 2014, our confidence in our portfolio's internal and external growth has allowed us to announce a 4% increase in our 2014 dividend payment rate. Our Board of Directors has approved a 2014 quarterly dividend payment rate of $0.795 per share, or $3.18 annually, beginning with the February 2014 dividend payment. Importantly, we expect that our rate of earnings growth next year can exceed our rate of dividend growth, allowing us to further drive down our payout ratios. Before turning to guidance, I'd like to point out several enhancements to our supplement this quarter, as we continue our concerted efforts to enhance our disclosure. Most notably on Page 16, we created a new page assisting NAV calculations, which provides Health Care REIT's pro rata share of both NOI and debt. Next, on Pages 5 and 8, we have added sequential same-store performance data over the trailing 5 quarters for both the seniors housing operating and life science portfolios. And finally, on Page 2, we provide new disclosure detailing our portfolio NOI concentration by asset type, and that's broken down by both country, as well as ranks by our top 20 MSAs. Turning last to guidance. We are increasing the midpoint of our FFO and FAD per share ranges by $0.02 today, based on the strength of our investment success and earnings results year-to-date, offset only slightly by our $400 million October debt offering. Both our new normalized 2013 FFO range of $3.74 to $3.80 per share, and FAD range of $3.29 to $3.35 per share represents 6% to 8% growth year-over-year. We continue to expect blended same-store cash NOI growth for the full year 2013 of 3.5%, driven by the continued strength of our seniors housing operating portfolio, which is now projected to generate very strong same-store NOI growth of approximately 7% for the year. As is typical for us, our guidance does not include an assumption for additional investments beyond those already announced. We do continue to expect approximately $500 million of dispositions for the year and, thus far, we've completed $407 million of dispositions at a blended yield on sale of 6.4%, including net gains on sales. And finally, we project a total of $286 million of development conversions this year at an average initial yield of 8.5%. Our capital expenditure forecast remains $67 million for the year, comprised of approximately $49 million associated with the seniors housing operating portfolio, with the remaining $18 million coming from our medical facilities portfolio. And finally, our G&A forecast for 2013 remains approximately $107 million to $108 million for the full year, which implies approximately $27 million to $28 million of G&A during the fourth quarter of 2013. That does conclude my prepared remarks, but I would like to leave you today with my note of confidence that we remain on excellent financial footing as we head into 2014. So at this point, operator, we would like to open the call up for questions please.